We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Domainex Ltd Wins Biotechnology Innovation Award
News

Domainex Ltd Wins Biotechnology Innovation Award

Domainex Ltd Wins Biotechnology Innovation Award
News

Domainex Ltd Wins Biotechnology Innovation Award

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Domainex Ltd Wins Biotechnology Innovation Award"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Domainex Ltd, a contract research organisation offering technology to solve expression of intractable gene targets and high quality computational and medicinal chemistry, won the Innovation in Enabling Biotechnology Award at the 2007 UK BioEntrepreneurial Company of the Year Awards, presented by UK Trade & Investment in London on July 4th.

More than 180 industry leaders attended the annual ceremony, which recognises innovation and entrepreneurship in the biotechnology industry.

Dr Renos Savva, one of the company’s founders and the CEO of Domainex, Dr Eddy Littler, received the award from Mr Andrew Cahn, CEO of UK Trade & Investment. “We are delighted to have been presented with this award, which recognises our commitment to developing new technologies for streamlining and accelerating the drug discovery process,” said Dr Savva.

Domainex Ltd has developed a high-throughput technology for producing soluble and stable protein fragments that are suitable for compound screening, structural biology studies or antibody production. The approach resolves the discovery ‘gap’ that exists between the vast amount of genomic information that is now available, and the accessibility of the corresponding proteins for use in target validation and drug discovery.

Dr Keith Powell, Chairman of Domainex, added, “We are a young, fast-growing London company, capable of reaching drug targets that were previously impossible to reach – and we are now in a position to move from drug target identification into drug development.”

Advertisement